MaxCyte, Inc. (MXCT) stock
Close on Nov 11, 2026Market cap $113.53MP/E –Yield –
MaxCyte, Inc. saw revenue fall 0.1% to $34.37M over the twelve months to Sep 30, 2026. Free cash flow was -$21.45M. At the latest close the market valued the company at $113.53M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $113.53M
- P/E ratio
- –
- Price to sales
- 3.30
- Price to book
- 0.75
- Dividend yield
- –
- Free cash flow yield
- -18.89%
Fundamentals
- Revenue
- $34.37M
- Net income
- -$27.98M
- EPS, diluted
- -$0.26
- Free cash flow
- -$21.45M
- Book value per share
- $1.46
- Diluted shares
- 104M
Trading
- Next earnings
- Mar 23, 2027 (estimated, after the close)
- Previous close
- $1.13
- Open
- $1.12
- Day's range
- $1.10 – $1.21
- Volume
- 2,123,358
- Average volume (20 days)
- 1,501,570
- Beta (5 years)
- 1.53
- 52-week range
- $0.64 – $1.80
- RSI (14 days)
- 37.1
- Volatility (1 year)
- 73.7%
- Relative volume
- 2.18×
- WACC
- 12.5%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | MXCT | S&P 500 | Difference | MXCT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +8.9% | -2.4% | +11.3 pts | ||
| 3 months | -11.3% | -1.2% | −10.1 pts | ||
| Year to date | -29.0% | +12.3% | −41.3 pts | ||
| 1 year | -29.0% | +12.4% | −41.5 pts | ||
| 3 years | -66.6% | +78.8% | −145.4 pts | -30.6% | +21.4% |
| 5 years | -91.5% | +75.2% | −166.6 pts | -38.9% | +11.9% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases MaxCyte filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About MaxCyte
Services-Commercial Physical & Biological Research
MaxCyte is a commercial cell engineering company that provides enabling platform technologies for cell therapeutics and cell-based research and development. Its primary offering is the proprietary ExPERT platform, which utilizes Flow Electroporation technology to deliver diverse molecules into eukaryotic cells. The ExPERT product family comprises five benchtop instruments—the DTx, ATx, STx, GTx, and VLx—along with specialized disposables such as processing assemblies, consumables like electroporation buffers, and software protocols. The company also provides gene editing assessment services through its SeQure Dx business. MaxCyte serves commercial cell therapy drug developers, biopharmaceutical corporations, academic centers, and government research bodies such as the U.S. National Institutes of Health.
Company profile, executives and historyMaxCyte stock: common questions
What is MaxCyte's stock price?
MXCT closed at $1.10 on Nov 11, 2026, down 2.65% on the day. Over the past 52 weeks it traded between $0.64 and $1.80.
What is MaxCyte's market cap?
MaxCyte was worth $113.53M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is MXCT's P/E ratio?
MaxCyte lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.26), so it has no meaningful P/E ratio.
How much revenue does MaxCyte make?
MaxCyte reported revenue of $34.37M for the twelve months to Sep 30, 2026, down 0.1% from a year earlier.
Does MaxCyte pay a dividend?
No. MaxCyte has not paid a cash dividend over the last twelve months.
When does MaxCyte report earnings next?
MaxCyte is expected to report Q4 FY2026 results on Mar 23, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has MXCT stock performed over the past year?
Including dividends, MXCT returned -29.0% over the past year, against +12.4% for the S&P 500.
How many MXCT shares are sold short?
2M shares were sold short at the latest FINRA report, 1.67% of the float, or 1.3 days of average trading volume.
Who are MaxCyte's competitors?
Companies most similar to MaxCyte by business, industry and size include OABI, FOXO, NRC, BIAF, CELU.
See a number that looks wrong?